[
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=dd232797cab74e9f47846033f3ef2bcd217d452b7625ce532b41ee4678c298a1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738602420,
      "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "id": 132557897,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=dd232797cab74e9f47846033f3ef2bcd217d452b7625ce532b41ee4678c298a1"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. - Update on Regulatory Review of Lecanemab for Early Alzheimer's disease in the European Union",
    "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD and...",
    "url": "https://finnhub.io/api/news?id=c1bd73486fe2530c637cdb2ee223448c7c0496f7832338f5284749043c92391e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738573458,
      "headline": "Biogen Inc. - Update on Regulatory Review of Lecanemab for Early Alzheimer's disease in the European Union",
      "id": 132520509,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD and...",
      "url": "https://finnhub.io/api/news?id=c1bd73486fe2530c637cdb2ee223448c7c0496f7832338f5284749043c92391e"
    }
  }
]